A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Inclusion Criteria: * Men or women at least 40 years old with a diagnosis of type 2 diabetes * Established cardiovascular disease, including at least 1 of the following: * Coronary artery disease (CAD) with any of the following: * Documented history of spontaneous myocardial infarction (MI) * ≥50% stenosis in 1 or more major coronary arteries, determined by invasive angiography * ≥50% stenosis in 2 or more major coronary arteries, determined by computed tomography coronary angiography (CTCA) * History of surgical or percutaneous coronary revascularization procedure * Cerebrovascular disease - any of the following: * Documented history of ischemic stroke * Carotid arterial disease with ≥50% stenosis, documented by carotid ultrasound, magnetic resonance imaging (MRI), or angiography * Carotid stenting or surgical revascularization * Peripheral arterial disease with either of the following: * Intermittent claudication and ankle-brachial index \<0.9 * Prior nontraumatic amputation or peripheral vascular procedure (eg, stenting or surgical revascularization), due to peripheral arterial ischemia * Note: Supporting medical documentation is required in all instances * HbA1c ≥7% (≥53 mmol/mol) and ≤10.5% (≤91.3 mmol/mol) based on central laboratory assessment at screening * Body mass index (BMI) ≥25 kg/m2 * At the time of signing the informed consent: Contraceptive use by men or women should be consistent with local regulations regardin…